A high-performance liquid chromatography and nuclear magnetic resonance spectroscopy-based analysis of commercially available praziquantel tablets

Jia Li; Yulan Wang; Alan Fenwick; T Andrew Clayton; Yu Y K Lau; Cristina Legido-Quigley; John C Lindon; Jürg Utzinger; Elaine Holmes

doi:10.1016/j.jpba.2007.06.017

A high-performance liquid chromatography and nuclear magnetic resonance spectroscopy-based analysis of commercially available praziquantel tablets

Jia Li, Yulan Wang, Alan Fenwick, T Andrew Clayton, Yu Y K Lau, Cristina Legido-Quigley, John C Lindon, Jürg Utzinger, Elaine Holmes

17 Citationer (Scopus)

Abstract

The amount of active ingredient in 20 commercially sourced batches of praziquantel (PZQ) tablets was determined using a high-performance liquid chromatography-ultraviolet (HPLC-UV) assay in conjunction with an anthentic, lot of PZQ powder. The general composition of each batch of tablets was also examined by means of (1)H nuclear magnetic resonance (NMR) spectroscopy and the NMR data were subjected to pattern recognition analysis by means of principal component analysis. The HPLC-UV results showed that each batch of PZQ tablets contained approximately the required amount of PZQ (600 mg per tablet). The NMR analysis showed a high degree of compositional variation between manufacturers, which caused by variation in excipients, along with some batch-to-batch variation in the tablets from a single manufacturer. Additionally, the PZQ tablets from one manufacturer were found to have an extra component (methyl-4-hydroxybenzoate) that was not detected in the other preparations.

Originalsprog	Engelsk
Tidsskrift	Journal of Pharmaceutical and Biomedical Analysis
Vol/bind	45
Udgave nummer	2
Sider (fra-til)	263-7
Antal sider	5
ISSN	0731-7085
DOI	https://doi.org/10.1016/j.jpba.2007.06.017
Status	Udgivet - 18 okt. 2007
Udgivet eksternt	Ja

Adgang til dokumentet

10.1016/j.jpba.2007.06.017

Citationsformater

Li, J., Wang, Y., Fenwick, A., Clayton, T. A., Lau, Y. Y. K., Legido-Quigley, C., Lindon, J. C., Utzinger, J., & Holmes, E. (2007). A high-performance liquid chromatography and nuclear magnetic resonance spectroscopy-based analysis of commercially available praziquantel tablets. Journal of Pharmaceutical and Biomedical Analysis, 45(2), 263-7. https://doi.org/10.1016/j.jpba.2007.06.017

A high-performance liquid chromatography and nuclear magnetic resonance spectroscopy-based analysis of commercially available praziquantel tablets. / Li, Jia; Wang, Yulan; Fenwick, Alan et al.
I: Journal of Pharmaceutical and Biomedical Analysis, Bind 45, Nr. 2, 18.10.2007, s. 263-7.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Li, J, Wang, Y, Fenwick, A, Clayton, TA, Lau, YYK, Legido-Quigley, C, Lindon, JC, Utzinger, J & Holmes, E 2007, 'A high-performance liquid chromatography and nuclear magnetic resonance spectroscopy-based analysis of commercially available praziquantel tablets', Journal of Pharmaceutical and Biomedical Analysis, bind 45, nr. 2, s. 263-7. https://doi.org/10.1016/j.jpba.2007.06.017

@article{e198967e99ea4d5da2fe2d68edb6f143,

title = "A high-performance liquid chromatography and nuclear magnetic resonance spectroscopy-based analysis of commercially available praziquantel tablets",

abstract = "The amount of active ingredient in 20 commercially sourced batches of praziquantel (PZQ) tablets was determined using a high-performance liquid chromatography-ultraviolet (HPLC-UV) assay in conjunction with an anthentic, lot of PZQ powder. The general composition of each batch of tablets was also examined by means of (1)H nuclear magnetic resonance (NMR) spectroscopy and the NMR data were subjected to pattern recognition analysis by means of principal component analysis. The HPLC-UV results showed that each batch of PZQ tablets contained approximately the required amount of PZQ (600 mg per tablet). The NMR analysis showed a high degree of compositional variation between manufacturers, which caused by variation in excipients, along with some batch-to-batch variation in the tablets from a single manufacturer. Additionally, the PZQ tablets from one manufacturer were found to have an extra component (methyl-4-hydroxybenzoate) that was not detected in the other preparations.",

keywords = "Anthelmintics/analysis, Chromatography, High Pressure Liquid/methods, Magnetic Resonance Spectroscopy/methods, Molecular Structure, Praziquantel/analysis, Principal Component Analysis, Quality Control, Tablets",

author = "Jia Li and Yulan Wang and Alan Fenwick and Clayton, {T Andrew} and Lau, {Yu Y K} and Cristina Legido-Quigley and Lindon, {John C} and J{\"u}rg Utzinger and Elaine Holmes",

year = "2007",

month = oct,

day = "18",

doi = "10.1016/j.jpba.2007.06.017",

language = "English",

volume = "45",

pages = "263--7",

journal = "Journal of Pharmaceutical and Biomedical Analysis",

issn = "0731-7085",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - A high-performance liquid chromatography and nuclear magnetic resonance spectroscopy-based analysis of commercially available praziquantel tablets

AU - Li, Jia

AU - Wang, Yulan

AU - Fenwick, Alan

AU - Clayton, T Andrew

AU - Lau, Yu Y K

AU - Legido-Quigley, Cristina

AU - Lindon, John C

AU - Utzinger, Jürg

AU - Holmes, Elaine

PY - 2007/10/18

Y1 - 2007/10/18

N2 - The amount of active ingredient in 20 commercially sourced batches of praziquantel (PZQ) tablets was determined using a high-performance liquid chromatography-ultraviolet (HPLC-UV) assay in conjunction with an anthentic, lot of PZQ powder. The general composition of each batch of tablets was also examined by means of (1)H nuclear magnetic resonance (NMR) spectroscopy and the NMR data were subjected to pattern recognition analysis by means of principal component analysis. The HPLC-UV results showed that each batch of PZQ tablets contained approximately the required amount of PZQ (600 mg per tablet). The NMR analysis showed a high degree of compositional variation between manufacturers, which caused by variation in excipients, along with some batch-to-batch variation in the tablets from a single manufacturer. Additionally, the PZQ tablets from one manufacturer were found to have an extra component (methyl-4-hydroxybenzoate) that was not detected in the other preparations.

AB - The amount of active ingredient in 20 commercially sourced batches of praziquantel (PZQ) tablets was determined using a high-performance liquid chromatography-ultraviolet (HPLC-UV) assay in conjunction with an anthentic, lot of PZQ powder. The general composition of each batch of tablets was also examined by means of (1)H nuclear magnetic resonance (NMR) spectroscopy and the NMR data were subjected to pattern recognition analysis by means of principal component analysis. The HPLC-UV results showed that each batch of PZQ tablets contained approximately the required amount of PZQ (600 mg per tablet). The NMR analysis showed a high degree of compositional variation between manufacturers, which caused by variation in excipients, along with some batch-to-batch variation in the tablets from a single manufacturer. Additionally, the PZQ tablets from one manufacturer were found to have an extra component (methyl-4-hydroxybenzoate) that was not detected in the other preparations.

KW - Anthelmintics/analysis

KW - Chromatography, High Pressure Liquid/methods

KW - Magnetic Resonance Spectroscopy/methods

KW - Molecular Structure

KW - Praziquantel/analysis

KW - Principal Component Analysis

KW - Quality Control

KW - Tablets

U2 - 10.1016/j.jpba.2007.06.017

DO - 10.1016/j.jpba.2007.06.017

M3 - Journal article

C2 - 17659859

SN - 0731-7085

VL - 45

SP - 263

EP - 267

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

IS - 2

ER -

A high-performance liquid chromatography and nuclear magnetic resonance spectroscopy-based analysis of commercially available praziquantel tablets

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater